Cambridge Investment Research Advisors Inc. Sells 1,035 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Cambridge Investment Research Advisors Inc. reduced its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX – Get Rating) by 7.3% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 13,125 shares of the biopharmaceutical company’s stock after selling 1,035 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Dynavax Technologies were worth $137,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Advisors Asset Management Inc. boosted its holdings in Dynavax Technologies by 498.0% in the 1st quarter. Advisors Asset Management Inc. now owns 2,362 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 1,967 shares during the period. Quantbot Technologies LP boosted its holdings in Dynavax Technologies by 940.7% in the 1st quarter. Quantbot Technologies LP now owns 2,508 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 2,267 shares during the period. Banque Cantonale Vaudoise bought a new position in Dynavax Technologies in the 2nd quarter worth approximately $67,000. Point72 Hong Kong Ltd purchased a new stake in Dynavax Technologies in the 1st quarter worth approximately $102,000. Finally, Captrust Financial Advisors lifted its stake in Dynavax Technologies by 1,116.0% in the 2nd quarter. Captrust Financial Advisors now owns 10,336 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 9,486 shares in the last quarter. 94.26% of the stock is owned by institutional investors.

Dynavax Technologies Price Performance

Shares of Dynavax Technologies stock opened at $11.35 on Tuesday. The firm has a market cap of $1.45 billion, a PE ratio of 5.48 and a beta of 1.37. Dynavax Technologies Co. has a 12-month low of $7.26 and a 12-month high of $17.48. The company has a quick ratio of 3.40, a current ratio of 3.82 and a debt-to-equity ratio of 0.44. The company’s fifty day simple moving average is $11.64 and its two-hundred day simple moving average is $12.20.

Dynavax Technologies (NASDAQ:DVAX – Get Rating) last announced its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.10. The business had revenue of $167.74 million for the quarter, compared to analyst estimates of $149.99 million. Dynavax Technologies had a net margin of 44.35% and a return on equity of 90.54%. As a group, equities analysts expect that Dynavax Technologies Co. will post 1.93 EPS for the current year.

Analysts Set New Price Targets

Several research firms have issued reports on DVAX. StockNews.com cut shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Monday, November 7th. JMP Securities initiated coverage on shares of Dynavax Technologies in a research report on Tuesday, September 27th. They set an “outperform” rating and a $22.00 price objective on the stock. Finally, The Goldman Sachs Group lowered their price objective on shares of Dynavax Technologies from $24.00 to $21.00 and set a “buy” rating on the stock in a research report on Friday, November 4th.

Insiders Place Their Bets

In other news, Director Andrew A. F. Hack sold 1,500,000 shares of Dynavax Technologies stock in a transaction dated Tuesday, December 6th. The shares were sold at an average price of $11.60, for a total transaction of $17,400,000.00. Following the sale, the director now owns 3,915,000 shares of the company’s stock, valued at approximately $45,414,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Andrew A. F. Hack sold 1,500,000 shares of Dynavax Technologies stock in a transaction dated Tuesday, December 6th. The shares were sold at an average price of $11.60, for a total transaction of $17,400,000.00. Following the sale, the director now owns 3,915,000 shares of the company’s stock, valued at approximately $45,414,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO David F. Novack sold 52,204 shares of the business’s stock in a transaction dated Tuesday, November 8th. The stock was sold at an average price of $12.47, for a total transaction of $650,983.88. Following the sale, the chief operating officer now directly owns 2,066 shares in the company, valued at approximately $25,763.02. The disclosure for this sale can be found here. Insiders own 9.31% of the company’s stock.

Dynavax Technologies Company Profile

(Get Rating)

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.